M

Mass General Brigham

Early-stage life science venture investor

Registered Nurse - Special Care Nursery

Part-TimeUpdated on 10/22/2026
$45.52 - $110/hr
Mid
Bachelor's
Newton, MA, USA
In PersonOnsite at 2014 Washington Street.
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • A nursing certificate or diploma is required; a Bachelor's Degree in Nursing is preferred.
  • A state Registered Nurse license is required.
  • Specialty-specific experience and any other experience stated in the individual posting are required; certifications or advanced training in the specialty area are preferred.
  • Strong interpersonal communication, problem-solving, and conflict-management skills are required.
  • Demonstrated clinical competence and experience as required by the specific job posting are required.
  • The role requires the physical ability to perform the listed activities, including frequent standing, walking, lifting with an assisted device, carrying, balancing, reaching, handling and fingering, and constant feeling, near and far vision, talking, and hearing.
  • The role involves work in patient-care environments with possible exposure to communicable diseases, hazardous materials, human waste, unpleasant elements, dirt, odors, cramped quarters, and angry, agitated, or combative patients.
Responsibilities
  • Provide direct and indirect nursing care to assigned patients using the nursing process, including assessment, planning, implementation, and evaluation, in accordance with professional standards and applicable regulations.
  • Oversee assigned team members and collaborate with multidisciplinary teams to provide population-specific care.
  • Assess patients' physical, psychological, spiritual, cultural, and social needs; individualize care to patients' abilities, circumstances, and practices; and update knowledge and skills to meet population-specific needs.
  • Apply knowledge of illness, injury, and disease to patient assessment and recognize symptoms requiring immediate intervention.
  • Develop and update individualized plans of care in collaboration with patients, families, significant others, and appropriate resources; evaluate responses to goals and interventions and revise plans as needed.
  • Engage patients and families as partners in care, provide emotional, psychological, spiritual, comfort, and hygiene support, advocate for patients, and inform them of their rights and responsibilities.
  • Implement clinical and technical aspects of care and physicians' orders according to standards of practice and care; respond appropriately to emergencies and changes in patients' physical or mental status.
  • Coordinate multidisciplinary resources to facilitate comprehensive discharge planning, anticipate discharge needs and barriers with case managers, and include the person primarily responsible for home care in patient teaching and discharge planning.
  • Maintain a safe and therapeutic environment, use two patient identifiers, follow infection-control and universal-precaution practices, OSHA standards, hazardous-material guidelines and isolation procedures, protect confidential information, and use restraints only after assessing need and considering alternatives.
  • Use equipment and supplies properly, perform point-of-care testing with proper technique and calibration, ensure equipment is operational and safe, and remove unsafe equipment from service.
  • Follow departmental policies and procedures, contribute to service quality, stay informed of changes, make independent decisions within nursing scope, and contribute to a cooperative work environment.
  • Participate in performance-improvement activities, evaluate patient-care outcomes, make recommendations for revisions to individualized plans, and incorporate improvement recommendations into daily practice.
  • Control patient-care costs through efficient management of supplies and services and suggestions for cost-containment approaches.
  • Ensure complete, accurate, timely patient-information communication and documentation, including discharge instructions and chronologically organized progress notes.
  • Administer medications and intravenous fluids safely and accurately; use the five rights, scan barcodes where applicable, understand drug actions and adverse reactions, verify or rectify medication records, check medication and infusion orders and pump settings, and report medication variances or process problems.
  • Assess patient and family education needs, formulate and implement an educational plan that accounts for learning barriers and cultural or spiritual needs, document education, evaluate learning outcomes, obtain feedback, and modify instruction as needed.
  • Take responsibility for performance and professional development, maintain clinical competence and required training, accept accountability for assigned patient care, and learn from constructive criticism.
  • Initiate and facilitate changes to improve nursing-care quality on the unit; collaborate with coworkers and other healthcare team members; communicate expectations to assigned team members; address conflicts appropriately; solve problems; and communicate critical patient information across the continuum of care.
  • Perform charge-nurse duties as needed, act as a resource and professional role model for peers and students, assist with orientation and ongoing support of new staff, and escalate patient-care concerns through the chain of command.
  • Manage urgent and emergent situations effectively and support management decisions, goals, and initiatives.
  • For the Device Clinic RN role, enroll, interrogate, and program outpatient pacemaker patients; identify abnormalities, malfunctions, and end-of-service indicators; notify cardiologists and assist with follow-up or replacement scheduling.
  • For the Device Clinic RN role, coordinate timely care with healthcare team members, educate patients and families about device function and clinic follow-up, forward information to referring physicians, and complete timely documentation and billing.
  • For the Device Clinic RN role, lead the device recall team; administer trans-telephonic monitoring, including purchase orders, billing issues, and reporting; oversee Cardiac Arrhythmia Service event monitoring; provide cross-coverage; serve as a resource to staff, departments, and administration; provide budgetary-goal input; maintain knowledge of hospital, department, and regulatory requirements; and participate in continuing education.
  • For the STAT RN role, assist with rapid responses and Code Blue events on inpatient units.
  • For the STAT RN role, assist with admissions and transfers of critically ill patients to the ICU from the Emergency Department, Operating Room, Post-Anesthesia Care Unit, medical/surgical units, and Labor and Delivery/Post-Partum units.
  • For the STAT RN role, assist with unstable or critically ill ICU-level patients in the Emergency Department, Post-Anesthesia Care Unit, and medical-surgical units; assist with intravenous access and phlebotomy; and assist in the ICU when census or acuity exceeds core staffing and additional resources are unavailable.
  • For the STAT RN role, assist with transport and supervision of patients requiring diagnostic testing off their unit, perform other assigned clinical duties when there are no in-house critical-care support needs, and work under the direct supervision of the Nursing Administrator and overall direction of the intensive-care nurse manager.
Desired Qualifications
  • A Bachelor's Degree in Nursing is preferred.
  • Certifications or advanced training in the specialty area are preferred.
  • For Adult GI, Critical Care/GI experience and ACLS within the first year are specified as required unless otherwise noted; CCGRN certification is preferred.
  • For the Assisted Reproductive Technologies Clinic, advanced knowledge of reproductive health and treatment options is expected; the ASRM RN certificate course must be completed within the first year, while the listed text does not mark these as preferences.
  • For the Cancer Center, three years of ambulatory oncology nursing experience and Oncology Nursing Society membership are strongly preferred.
  • For the Cardiovascular Center, Cardiac ICU, CCU, Cardiac Surgery, or Cath Lab experience; proficiency in intravenous catheter insertion and intravenous sedation in an acute procedural setting are preferred.
  • For the Device Clinic, HRS/NASP certification is preferred.
  • For the Emergency Department, CEN or CCRN certification is preferred.
  • For Labor and Delivery/AETU, fetal-monitoring experience is preferred.
  • For Maternal Fetal Medicine, ACLS is preferred.
  • For Med/Surg, telemetry experience is preferred.
  • For Mother/Baby, fetal-monitoring experience is preferred.
  • For the Operating Room, completion of a peri-operative nursing program and AORN certification are preferred.
  • For PACU/Henderson, CPAN/CAPA certification is preferred.
  • For Primary Care Triage RN, Ambulatory Care Nursing Certification ANCC RN-BC is preferred.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.

Associated Press
May 13th, 2026
Violet Therapeutics raises $4.75M to advance synaptic preservation therapy for neurodegenerative diseases

Violet Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, has raised $4.75 million in a seed extension round led by Lifespan Vision Ventures. Dementia Discovery Fund, UTEC, Ono Venture Investment and Mass General Brigham Ventures also participated. The Cambridge-based company will use the funding to advance its lead small molecule programme targeting EphB3 through IND-enabling activities. The therapy aims to halt and potentially reverse cognitive decline through glial-mediated synaptic preservation, addressing synaptic loss, the strongest predictor of cognitive decline in Alzheimer's and other neurodegenerative diseases. Violet's proprietary CONNECT platform maps cell-cell interaction networks to identify novel therapeutic targets. Founded by Mass General Brigham Ventures with researchers from Brigham and Women's Hospital, the company is developing first-in-class CNS therapies.